Plasma adsorption for adults with liver failure in the ICU
Part of Digestive system clinical trials.
This trial studies a treatment called the Double Plasma Molecular Adsorption System (DPMAS) for people with acute-on-chronic liver failure while they are in the ICU. It aims to see whether filtering certain substances from blood can improve outcomes and safety for critically ill patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- Doctors have diagnosed acute-on-chronic liver failure based on APASL criteria
- You are currently admitted to an intensive care unit (ICU)
- You are not pregnant
- You have not had steroid treatment recently
- You do not have conditions like severe low white blood cell counts or a known allergy to DPMAS
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a combination approach called DPMAS and low-volume plasma exchange for people with hepatitis B–related acute-on-chronic liver failure. If you qualify, the goal is to improve your liver function and reduce serious complications from liver failure.
This trial tests a new treatment called HepaCure for people with acute-on-chronic liver failure (a sudden worsening of liver function in someone with long-term liver disease). The goal is to see if it is safe and can help improve liver function.
This trial tests whether a treatment called therapeutic plasma exchange (a process that filters your blood) can help improve the function of other organs in people with severe liver failure. It aims to see if this treatment leads to better outcomes and to find markers that predict who will benefit.
This trial tests if a special blood-filtering method combined with plasma exchange can help people with severe liver failure and sepsis. It aims to reduce inflammation and improve survival.
This trial tests a device called CytoSorb that filters the blood to reduce inflammation in patients with sudden worsening of chronic liver disease. It may help support organ function and recovery.
This trial tests a new drug called AS1501 for people with acute-on-chronic liver failure (a sudden worsening of chronic liver disease). It aims to see if the drug can help improve liver function and reduce the need for a liver transplant. You may be eligible if you are in the early or middle stage of this condition and have a specific blood marker (high TRAIL level).
Hear when a new Acute-On-Chronic Liver Failure trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.